Kalprotektin, fekal
Kod:6012
| Kabi | Kalprotektin (fekal) |
|---|
Tahlil ma'lumotlari
Tadqiqot usuli
- Ferment immunoanalizi (EIA)
Kutilayotgan natija topshirish vaqti
1 kun
Maxsus tayyorlik
- Do not use rectal suppositories for 48–72 hours before collecting the stool sample.
- Do not submit a specimen collected within 5–7 days after an intestinal endoscopic procedure.
Qanday foydalanish
Kalprotektin, fekal (najasdagi kalprotektin) gumon qilingan yallig‘lanishli ichak kasalliklarini baholashda va oshqozon-ichak simptomlarining yallig‘lanishli sabablarini iritabli ichak sindromi hamda qorin shikoyatlari yoki oshqozon-ichakdan qon ketishining boshqa no-yallig‘lanishli izohlaridan ajratishda qo‘llaniladi. Ma’lum yallig‘lanishli ichak kasalligi bo‘lgan bemorlarda fekal kalprotektin kasallik faolligini baholashni qo‘llab-quvvatlaydi va vaqt mobaynida davolashga javobni monitoring qilish uchun ishlatilishi mumkin.
Cheklovlar
Najasdagi kalprotektin neytrofillarning ichak bo‘shlig‘iga o‘tishini aks ettiradi va ichak shilliq qavati yallig‘lanishining noinvaziv ko‘rsatkichi sifatida ishlaydi. Konsentratsiyalar yarali kolit va Kron kasalligi kabi yallig‘lanishli ichak kasalliklarida ortadi va odatda yallig‘lanish faolligi darajasi bilan parallel kechadi, funksional holatlar, masalan iritabli ichak sindromida esa ko‘rsatkichlar odatda me’yor chegaralarida bo‘ladi. Tahlil kasallikka xos emas; oshishlar oshqozon-ichak traktining turli yallig‘lanish kasalliklarida kuzatilishi mumkin. Shuning uchun talqin qilish simptomlar, endoskopik topilmalar, gistologiya va boshqa laborator ma’lumotlar bilan integratsiyalangan holda amalga oshirilishi lozim. Yallig‘lanishli ichak kasalliklari mezbon va mikrobiom o‘rtasidagi disregulyatsiyalangan immun o‘zaro ta’sirlar natijasida kelib chiqadi va asoratlar xavfining ortishi bilan bog‘liq; boshqaruv yallig‘lanishni nazorat qilish va mukozal shifoga erishishga qaratilgan bosqichma-bosqich yondashuvga amal qiladi.
| Referens oraliq |
| ||||
|---|---|---|---|---|---|
| Ko'rsatmalar | Cramping abdominal pain with altered intestinal motility, Change in bowel habits with mucus in the stool, Unexplained weight loss, Fever, Excessive sweating (hyperhidrosis), General malaise or fatigue, Joint pains (arthralgia), Poor growth or delayed development in children, Visible blood in stool (hematochezia), Perianal complications, including fistulae or abscesses, Constipation, Pain localized to the right lower quadrant or around the umbilicus, Nausea, Vomiting |
Namunangiz talablari
| Namunangiz | Najis |
|---|---|
| Container | Steril najas idishi |
References
J. Walkowiak, S. Nousia-Arvanitakis, J. Henker, S. Stern, M. Sinaasappel, J.A. Dodge. Indirect pancreatic function tests in children. J Pediatr Gastroenterol Nutr. 2005;40(2):107–114.
Aomatsu T, Yoden A, Matsumoto K, et al. Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci. 2011 Aug;56(8):2372-7.
Damms A, Bischoff SC. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int J Colorectal Dis. 2008 Oct;23(10):985-92.
Jellema P, van der Windt DAWM, Schellevis FG, van der Horst HE. Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care. Aliment Pharmacol Ther. 2009;30(7):695-706.
Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis. 2009;41(1):56-66.
Van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369.
The Use of Fecal Calprotectin Testing in Paediatric Disorders: A Position Paper of the European Society for Paediatric Gastroenterology and Nutrition Gastroenterology Committee. 2021.
Oord T, Hornung N. Fecal calprotectin in healthy children. Scand J Clin Lab Invest. 2014.